{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:19:00Z","timestamp":1772165940779,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This analysis evaluates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A simple, short-term model was used to compare the treatment costs and outcomes associated with hypoglycaemic events with degludec versus glargine U100 in patients with T1DM and T2DM from the perspective of the Bulgarian National Health Insurance Fund. Cost-effectiveness was analysed over a 1-year time horizon using data from clinical trials. The incremental cost-effectiveness ratio (ICER) was the main outcome measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In Bulgaria, degludec was highly cost-effective versus glargine U100 in people with T1DM and T2DM. The ICERs were estimated to be 4493.68 BGN\/quality-adjusted life year (QALY) in T1DM, 399.11 BGN\/QALY in T2DM on basal oral therapy (T2DM\n                      <jats:sub>BOT<\/jats:sub>\n                      ) and 7365.22 BGN\/QALY in T2DM on basal bolus therapy (T2DM\n                      <jats:sub>B\/B<\/jats:sub>\n                      ), which are below the cost-effectiveness threshold of 39,619 BGN in Bulgaria. Degludec was associated with higher insulin costs in all three patient groups; however, savings from a reduction in hypoglycaemic events with degludec versus glargine U100 partially offset these costs. Sensitivity analysis demonstrated that the results were robust and largely insensitive to variations in input parameters. At a willingness-to-pay threshold of 39,619 BGN\/QALY, the probability of degludec being cost-effective versus glargine U100 was 60.0% in T1DM, 99.4% in T2DM\n                      <jats:sub>BOT<\/jats:sub>\n                      and 91.3% in T2DM\n                      <jats:sub>B\/B<\/jats:sub>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Degludec is a cost-effective alternative to biosimilar glargine U100 for patients with T1DM and T2DM in Bulgaria. Degludec could be of particular benefit to those patients suffering recurrent hypoglycaemia and those who require additional flexibility in the dosing of insulin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-019-0460-6","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T09:03:02Z","timestamp":1575363782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-5280","authenticated-orcid":false,"given":"Monika","family":"Russel-Szymczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasil","family":"Valov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Savova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoela","family":"Manova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"460_CR1","unstructured":"International Diabetes Federation (IDF). Diabetes atlas - 8th edition. Available at: http:\/\/www.diabetesatlas.org\/."},{"issue":"4","key":"460_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2337\/dc12-2625","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033\u201346.","journal-title":"Diabetes Care"},{"issue":"7","key":"460_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s00125-002-0858-x","volume":"45","author":"B Jonsson","year":"2002","unstructured":"Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45(7):S5\u201312.","journal-title":"Diabetologia."},{"issue":"5","key":"460_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2337\/dci18-0007","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917\u201328.","journal-title":"Diabetes Care"},{"issue":"7258","key":"460_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ."},{"issue":"14","key":"460_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977\u201386.","journal-title":"N Engl J Med"},{"key":"460_CR7","volume-title":"Good clinical practice guidelines on diabetes mellitus","author":"Bulgarian Society of Endocrinology","year":"2016","unstructured":"Bulgarian Society of Endocrinology. Good clinical practice guidelines on diabetes mellitus. 2016."},{"issue":"12","key":"460_CR8","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"2","key":"460_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2337\/dc10-1710","volume":"34","author":"D Giugliano","year":"2011","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510\u20137.","journal-title":"Diabetes Care"},{"key":"460_CR10","volume-title":"Clinical Guidelines Task Force. Global guideline for type 2 diabetes","author":"International Diabetes Federation (IDF)","year":"2012","unstructured":"International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global guideline for type 2 diabetes, 2012. Available at https:\/\/www.idf.org\/e-library\/guidelines\/79-global-guideline-for-type-2-diabetes"},{"issue":"Suppl 1","key":"460_CR11","first-page":"S1","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S1\u2013S153.","journal-title":"Diabetes Care"},{"issue":"7","key":"460_CR12","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/j.1464-5491.2012.03586.x","volume":"29","author":"BT Blak","year":"2012","unstructured":"Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29(7):e13\u201320.","journal-title":"Diabet Med"},{"issue":"1","key":"460_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/cen.12119","volume":"80","author":"P de Pablos-Velasco","year":"2014","unstructured":"de Pablos-Velasco P, Parhofer KG, Bradley C, Eschwege E, Gonder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80(1):47\u201356.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"460_CR14","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.2337\/dc10-2099","volume":"34","author":"L Govan","year":"2011","unstructured":"Govan L, Wu O, Briggs A, Colhoun HM, Fischbacher CM, Leese GP, et al. Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes research network epidemiology group. Diabetes Care. 2011;34(9):1992\u20137.","journal-title":"Diabetes Care"},{"key":"460_CR15","unstructured":"NHS Health & Social Care Information Centre. National Diabetes Audit 2011\u20132012; Report 1: Care Processes and Treatment Targets, Available at http:\/\/content.digital.nhs.uk\/catalogue\/PUB12421\/nati-diab-audi-11-12-care-proc-rep.pdf."},{"issue":"5","key":"460_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00508-016-1143-1","volume":"129","author":"M Cokolic","year":"2017","unstructured":"Cokolic M, Lalic NM, Micic D, Mirosevic G, Klobucar Majanovic S, Lefterov IN, et al. Patterns of diabetes care in Slovenia, Croatia, Serbia, Bulgaria and Romania. Wien Klin Wochenschr. 2017;129(5):192\u2013200.","journal-title":"Wien Klin Wochenschr"},{"issue":"539","key":"460_CR17","first-page":"455","volume":"57","author":"MJ Calvert","year":"2007","unstructured":"Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57(539):455\u201360.","journal-title":"Br J Gen Pract"},{"issue":"12","key":"460_CR18","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/j.1464-5491.2007.02279.x","volume":"24","author":"A Rubino","year":"2007","unstructured":"Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24(12):1412\u20138.","journal-title":"Diabet Med"},{"issue":"11","key":"460_CR19","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28(11):2673\u20139.","journal-title":"Diabetes Care"},{"issue":"10","key":"460_CR20","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"460_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","volume":"53","author":"H Haahr","year":"2014","unstructured":"Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787\u2013800.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"460_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"460_CR23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/dom.12938","volume":"19","author":"T Heise","year":"2017","unstructured":"Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U\/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"460_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/1932296817731422","volume":"12","author":"T Heise","year":"2018","unstructured":"Heise T, Kaplan K, Haahr HL. Day-to-day and within-day variability in glucose-lowering effect between insulin Degludec and insulin Glargine (100 U\/mL and 300 U\/mL): a comparison across studies. J Diabetes Sci Technol. 2018;12(2):356\u201363.","journal-title":"J Diabetes Sci Technol"},{"key":"460_CR25","unstructured":"European Medicines Agency. Tresiba\u00ae (insulin degludec) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/tresiba-epar-product-information_en.pdf."},{"issue":"1 Suppl","key":"460_CR26","first-page":"21","volume":"62","author":"SK Wangnoo","year":"2014","unstructured":"Wangnoo SK, Chowdhury S, Rao PV. Treating to target in type 2 diabetes: the BEGIN trial programme. J Assoc Physicians India. 2014;62(1 Suppl):21\u20136.","journal-title":"J Assoc Physicians India"},{"issue":"2","key":"460_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","volume":"5","author":"J Vora","year":"2014","unstructured":"Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diab Therapy. 2014;5(2):435\u201346.","journal-title":"Diab Therapy"},{"issue":"2","key":"460_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"R Ratner","year":"2013","unstructured":"Ratner R, Gough SC, Mathieu C, Prato SD, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin Degludec compared with insulin Glargine in type 2 and type 1 Diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"460_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/dom.13149","volume":"20","author":"T Siegmund","year":"2018","unstructured":"Siegmund T, Tentolouris N, Knudsen ST, Lapolla A, Prager R, Phan TM, et al. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes Obes Metab. 2018;20(3):689\u201397.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"460_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3111\/13696998.2014.975234","volume":"18","author":"M Evans","year":"2015","unstructured":"Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice-a case-based evaluation. J Med Econ. 2015;18(2):96\u2013105.","journal-title":"J Med Econ"},{"issue":"5","key":"460_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/heapol\/czl018","volume":"21","author":"F Sassi","year":"2006","unstructured":"Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21(5):402\u20138.","journal-title":"Health Policy Plan"},{"key":"460_CR32","volume-title":"Report of the Commission on Macroeconomics and Health","author":"Macroeconomics and health: investing in health for economic development","year":"2001","unstructured":"Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/42435\/1\/924154550X.pdf"},{"issue":"2","key":"460_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s13300-017-0236-9","volume":"8","author":"M Evans","year":"2017","unstructured":"Evans M, Chubb B, Gundgaard J. Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus. Diab Therapy. 2017;8(2):275\u201391.","journal-title":"Diab Therapy"},{"issue":"3","key":"460_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s13300-018-0426-0","volume":"9","author":"N Lalic","year":"2018","unstructured":"Lalic N, Russel-Szymczyk M, Culic M, Tikkanen CK, Chubb B. Cost-effectiveness of insulin Degludec versus insulin Glargine U100 in patients with type 1 and type 2 Diabetes mellitus in Serbia. Diab Therapy. 2018;9(3):1201\u201316.","journal-title":"Diab Therapy"},{"issue":"2","key":"460_CR35","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.5504\/BBEQ.2013.0001","volume":"27","author":"M Doneva","year":"2013","unstructured":"Doneva M, Valov V, Borisova A-M, Tankova T, Savova A, Manova M, et al. Comparative Analysis of the Cost of Insulin Treated Patients in Bulgaria. Biotechnol Biotechnologic Equip. 2013;27(2):3748\u201352.","journal-title":"Biotechnol Biotechnologic Equip"},{"issue":"6","key":"460_CR36","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","volume":"50","author":"UK Hypoglycaemia Study Group","year":"2007","unstructured":"UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140\u20137.","journal-title":"Diabetologia."},{"issue":"12","key":"460_CR37","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1185\/03007995.2012.743457","volume":"28","author":"M Brod","year":"2012","unstructured":"Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin. 2012;28(12):1947\u201358.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"460_CR38","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3111\/13696998.2013.852099","volume":"16","author":"A Ericsson","year":"2013","unstructured":"Ericsson A, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ. 2013;16(12):1442\u201352.","journal-title":"J Med Econ"},{"issue":"1","key":"460_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/dme.12261","volume":"31","author":"CG Ostenson","year":"2014","unstructured":"Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92\u2013101.","journal-title":"Diabet Med"},{"key":"460_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/dme.12844","volume":"33","author":"SR Heller","year":"2016","unstructured":"Heller SR, Frier BM, Herslov ML, Gundgaard J, Gough SC. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33:471\u20137.","journal-title":"Diabet Med"},{"issue":"3","key":"460_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","volume":"12","author":"KS Boye","year":"2011","unstructured":"Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219\u201330.","journal-title":"Eur J Health Econ"},{"issue":"11","key":"460_CR42","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3111\/13696998.2013.846262","volume":"16","author":"M Evans","year":"2013","unstructured":"Evans M, Jensen HH, Bogelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013;16(11):1357\u201365.","journal-title":"J Med Econ"},{"issue":"3","key":"460_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13696998.2016.1245663","volume":"20","author":"RF Pollock","year":"2017","unstructured":"Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. J Med Econ. 2017;20(3):213\u201320.","journal-title":"J Med Econ"},{"issue":"4","key":"460_CR44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dom.12250","volume":"16","author":"M Evans","year":"2014","unstructured":"Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes Obes Metab. 2014;16(4):366\u201375.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"460_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3111\/13696998.2014.971160","volume":"18","author":"M Evans","year":"2015","unstructured":"Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2015;18(1):56\u201368.","journal-title":"J Med Econ"},{"issue":"Suppl 1","key":"460_CR46","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1177\/1474651410377558","volume":"11","author":"BM Frier","year":"2011","unstructured":"Frier BM. The economic costs of hypoglycaemia. Br J Diabetes Vasc Dis. 2011;11(Suppl 1):S10\u2013S2.","journal-title":"Br J Diabetes Vasc Dis"},{"issue":"2","key":"460_CR47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/dc14-0920","volume":"38","author":"K Khunti","year":"2015","unstructured":"Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316\u201322.","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"460_CR48","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/S1262-3636(10)70470-5","volume":"36","author":"AJ Graveling","year":"2010","unstructured":"Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab. 2010;36(Suppl 3):S64\u201374.","journal-title":"Diabetes Metab"},{"issue":"9","key":"460_CR49","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dom.12689","volume":"18","author":"K Khunti","year":"2016","unstructured":"Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic M, Enters-Weijnen C, Forsen T, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907\u201315.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"460_CR50","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/03007995.2016.1277194","volume":"33","author":"L Landstedt-Hallin","year":"2017","unstructured":"Landstedt-Hallin L, Gundgaard J, Ericsson A, Ellfors-Zetterlund S. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr Med Res Opin. 2017;33(4):647\u201355.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"460_CR51","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29(5):682\u20139.","journal-title":"Diabet Med"},{"key":"460_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.diabres.2017.05.004","volume":"130","author":"K Khunti","year":"2017","unstructured":"Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic M, Enters-Weijnen C, Forsen T, et al. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2017;130:121\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"460_CR53","volume-title":"Facts and stats","author":"Diabetes UK","year":"2016","unstructured":"Diabetes UK. Facts and stats 2016. Available at: https:\/\/www.diabetes.org.uk\/Documents\/Position%20statements\/DiabetesUK_Facts_Stats_Oct16.pdf."},{"issue":"1","key":"460_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","volume":"318","author":"W Lane","year":"2017","unstructured":"Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, et al. Effect of insulin Degludec vs insulin Glargine U100 on hypoglycemia in patients with type 1 Diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318(1):33\u201344.","journal-title":"JAMA."},{"issue":"1","key":"460_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"C Wysham","year":"2017","unstructured":"Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of insulin Degludec vs insulin Glargine U100 on hypoglycemia in patients with type 2 Diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45\u201356.","journal-title":"JAMA."},{"issue":"5","key":"460_CR56","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s13300-018-0478-1","volume":"9","author":"M Evans","year":"2018","unstructured":"Evans M, Mehta R, Gundgaard J, Chubb B. Cost-effectiveness of insulin degludec vs. insulin glargine U100 in type 1 and type 2 diabetes mellitus in a UK setting. Diab Therapy. 2018;9(5):1919\u201330.","journal-title":"Diab Therapy"},{"issue":"6","key":"460_CR57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12325-013-0036-1","volume":"30","author":"A Philis-Tsimikas","year":"2013","unstructured":"Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin Degludec once-daily in type 2 Diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013;30(6):607\u201322.","journal-title":"Adv Ther"},{"issue":"8","key":"460_CR58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723\u201332.","journal-title":"N Engl J Med"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-019-0460-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T19:20:26Z","timestamp":1606850426000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-019-0460-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1186\/s12902-019-0460-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.14752\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14752\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14752\/v2","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Alexandra Savova and Manoela Manova have nothing to declare. Monika Russel-Szymczyk and Vasil Valov are employees of Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}